Acquired hemophilia A (AHA) is a rare autoimmune disease characterized by inhibitory autoantibodies against endogenous factor VIII (FVIII).1 Treatment of AHA is based on controlling bleeding and eradicating inhibiting antibodies.2 Bypassing agents (BPAs) control bleeding by avoiding the need for FVIII to generate thrombin.3 These agents carry a risk of thromboembolic events that may be enhanced by patients’ comorbid conditions.1,4 High-dose replacement therapy with human FVIII (hFVIII) concentrates is used to increase FVIII levels when inhibitor titers are low [<10 Bethesda units (BU)/mL]. This evidence concerns the gene F8 and autoimmune disease.